Clinical trials: T2DM (Type 2 Diabetes Mellitus)
HbA1c, Self-Efficacy
IMPACT OF DIABETES HEALTHCARE PROGRAM ON GLYCEMIC CONTROL, SELF-EFFICACY AND DIABETES KNOWLEDGE AMONG TYPE-II DIABETICS IN ISLAMABAD PAKISTAN
Type-II Diabetes Mellitus is a significant public health challenge in Pakistan, characterized by a growing prevalence and substantial economic burden.
- Conditions
- HbA1c, Self-Efficacy, Diabetes Knowledge
- Trial name
- NCT06719076
- Testing
- Diabetes Healthcare Program (DHCP)
- Where
- Pakistan
- Volunteers
- 128 people
- Sponsor
- Health Services Academy, Islamabad, Pakistan
Diabetes Mellitus, Type 2, Insulin Resistance
Effects of a Plant-Based Diet on Insulin Requirements and Obesity Markers in Obese Adults With T2DM
This is a crossover study utilizing a Dietary Approaches to Stop Hypertension (DASH) diet and a whole-food, plant-based diet among subjects with type 2 diabetes who require insulin.
- Conditions
- Diabetes Mellitus, Type 2, Insulin Resistance, Obesity, Nutritional and Metabolic Disease
- Trial name
- NCT04048642
- Testing
- DASH, Whole-Food, Plant-Based
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Rochester
Type 2 Diabetes
Open Label Safety & Pharmacodynamic Study 24Wk w/DIO-902 Combo w/Metformin & Atorvastatin in T2DM Patients
DiObex Inc. is developing an experimental drug (DIO-902) that is made up of part of the ketoconazole molecule for the treatment of elevated blood glucose associated with type 2 diabetes mellitus.
- Trial name
- NCT00622089
- Testing
- DIO-902
- Where
- 24 sites in United States, Australia and 1 more
- Volunteers
- 150 people
- Sponsor
- DiObex
Type 2 Diabetes Mellitus (T2DM)
The Effect of Healthy Nutrition and Functional Foods Education Based on the Health Promotion Model for Individuals With Type 2 Diabetes on Healthy Lifestyle Behaviors and Self-Efficacy in Diabetes: Randomized Controlled Study
Non-communicable diseases (NCDs) are defined by the World Health Organization (WHO) as "slowly progressing and long-lasting diseases, health problems that require continuous care due to the combination of genetic, physiological…
- Trial name
- NCT06721546
- Testing
- Nursing interventions, reminder messages, Telephone counseling
- Where
- Turkey (Türkiye)
- Volunteers
- 86 people
- Sponsor
- Necmettin Erbakan University
Diabetes, Diabetes Mellitus, Type 2
Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C
12 week study to assess the LDL-C lowering efficacy, other lipid and glycemic measures, and safety of bempedoic acid/ezetimibe FDC compared to ezetimibe and placebo in patients with type 2 diabetes (T2D) and elevated LDL-C
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Cholesterolemia
- Trial name
- NCT03531905
- Testing
- Bempedoic acid + Ezetimibe FDC Oral Tablet, Ezetimibe 10 mg Oral Tablet
- Where
- 4 sites in United States
- Volunteers
- 242 people
- Sponsor
- Esperion Therapeutics, Inc.
Type 2 Diabetes Mellitus
A PK-PD Study of PSN821 in Type 2 Diabetes Patients (T2DM)
The purpose of this study is to investigate the pharmacokinetics and pharmacodynamics of PSN821 in patients with type 2 diabetes.
- Trial name
- NCT01386099
- Testing
- PSN821
- Where
- 4 sites in South Africa
- Volunteers
- 66 people
- Sponsor
- Prosidion Ltd.
Type 2 Diabetes Mellitus
A Clinical Study to Investigate if SAR425899 Binds to the Liver and Pancreas in Overweight to Obese Type 2 Diabetes Mellitus Patients
Primary Objectives: To assess in overweight to obese T2DM patients: The glucagon receptor occupancy of SAR425899 at two dose levels in the human liver with positron-emission tomography (PET) imaging using…
- Trial name
- NCT03350191
- Testing
- SAR425899, [68Ga] Ga-DO3A-VS-Cys40-Tuna-2 (glucagon receptor tracer), [68Ga] Ga-DO3A-VS-Cys40-Exendin-4 (GLP-1 receptor tracer)
- Where
- Sweden
- Volunteers
- 13 people
- Sponsor
- Sanofi
Type 2 Diabetes (T2DM), Glycemic Control
Impact of PharmaTE Trial on Glycemic Control, Diabetes Knowledge, Medication Adherence and Quality of Life in Type 2 Diabetes Patients: A Mixed-Method Study Protocol
The goal of this clinical trial is to find out whether a pharmacist-led tele-educational program (PharmaTE trial) can help people with type 2 diabetes manage their condition better.
- Conditions
- Type 2 Diabetes (T2DM), Glycemic Control, Diabetes Knowledge, Medication Adherence
- Trial name
- PharmaTE (NCT07043816)
- Testing
- PharmaTE Trial
- Volunteers
- 154 people
- Sponsor
- Rabia Hussain
Obesity Disease
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease
The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight and proportion of participants with ≥ 5% reduction in body weight.
- Trial name
- MARITIME-3-J (NCT06987695)
- Testing
- Maridebart cafraglutide
- Where
- 30 sites in Japan
- Volunteers
- 279 people
- Sponsor
- Amgen
Type 2 Diabetes
A Phase 3 Study of HS-20094 in Patients With T2DM
The study is being conducted to evaluate the efficacy and safety of HS-20094 once weekly (QW) in subjects with type 2 diabetes mellitus not adequately controlled with metformin monotherapy or in combination with SGLT2 inhibitors…
- Trial name
- NCT07156539
- Testing
- HS-20094 Injection, Dulaglutide Injection
- Where
- 2 sites in China
- Volunteers
- 546 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Diabetes
Comparing the Clinical Characteristics of Male LADA, T1DM and T2DM Patients
Diabetes is a common chronic disease in most parts of the world. Diabetes-related complications are harmful to the human body. Different types of diabetes have different levels of harm to the human body.
- Trial name
- LADA (NCT04618354)
- Testing
- No interventions
- Where
- China
- Volunteers
- 632 people
- Sponsor
- Shanghai 10th People's Hospital
Diabetes, Type 2
The Study to Investigate the Contribution of Basal and Postprandial Glucose to Overall Hyperglycemia in T2DM
There was no any China mainland data showing the contribution of BBG and PBG to HbA1c in T2DM patients treated with OADs using the CGM method.
- Trial name
- NCT02648685
- Where
- China
- Volunteers
- 337 people, healthy volunteers welcome
- Sponsor
- West China Hospital
Diabetes
A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose
A Study to Assess the Effect of CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose in Obese Male Subjects and Subjects with T2DM.
- Trial name
- NCT04973111
- Testing
- CT-868 as SC Injection, Active Comparator as SC Injection
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Carmot Therapeutics, Inc.
Type 2 Diabetes Mellitus, Diabetic Kidney Disease
Renal Oxygenation, Oxygen Consumption and Hemodynamic Kinetics in Type 2 DIabetes: an Ertugliflozin Study.
Current study will render insight in to the role of renal hypoxia in the diabetic kidney and is able to associate its finding with measurements of renal perfusion and glomerular filtration rate.
- Conditions
- Type 2 Diabetes Mellitus, Diabetic Kidney Disease, Diabetic Nephropathy, Renal Hypoxia
- Trial name
- ROCKIES (NCT04027530)
- Testing
- Ertugliflozin 15 mg
- Where
- Netherlands
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Amsterdam UMC, location VUmc
Type 2 Diabetes Mellitus (T2DM), Obesity
A Study to Learn How Different Amounts of PF-06954522 Are Tolerated and Act in Adults With Type 2 Diabetes Mellitus
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of multiple escalating oral doses of PF-06954522 in adult participants with inadequately controlled type 2 diabetes…
- Trial name
- NCT06279234
- Testing
- Rosuvastatin, Midazolam, Omeprazole
- Where
- 2 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus
A 6-month Clinical Study to Evaluate the Effect of a Digital Disease Management Tool in Patients With T2DM
Type 2 diabetes mellitus is a complex, chronic disease that requires a comprehensive treatment plan aimed at meeting multitude therapeutic targets associated with micro- and macro-vascular risk reduction.
- Trial name
- NCT03090464
- Testing
- Use of digital disease management tool
- Where
- 46 sites in United States
- Volunteers
- 328 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years
A trial of patients aged 10-24 years with type 2 diabetes mellitus to evaluate the comparative efficacy and safety between dapagliflozin and Placebo.
- Trial name
- NCT02725593
- Testing
- Dapagliflozin
- Where
- 42 sites in United States, Hungary and 5 more
- Volunteers
- 72 people
- Sponsor
- AstraZeneca
Metabolic Associated Fatty Liver Disease, Type 2 Diabetes (T2DM)
Glucagon Resistance in Patients With MASLD and T2DM
The goal of this clinical trial is to investigate the sensitivity to glucagon in patients with type 2 diabetes mellitus (T2DM), with and without metabolic associated fatty liver disease (MASLD).
- Trial name
- NCT07246421
- Testing
- Glugagon
- Where
- Denmark
- Volunteers
- 24 people
- Sponsor
- University of Aarhus
Type 2 Diabetes Mellitus (T2DM)
Effectiveness of and Implementation Strategies for 'Disfrutando'.
Despite much research that has focused on enhancing type 2 diabetes mellitus (T2DM) health outcomes for high burden populations, more remains to be done.
- Trial name
- Disfrutando 2 (NCT07023406)
- Testing
- Disfrutando
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- University of Missouri-Columbia
Type 2 Diabetes
Educative Intervention to Improve Type 2 Diabetes Mellitus Control in Corrientes
Objective: To evaluate the effect of system interventions (data recording procedures and complete coverage of medications and supplies) with or without physician and/or patient education, upon the psychological, clinical…
- Trial name
- PRODIACOR (NCT01456806)
- Testing
- Education
- Where
- Argentina
- Volunteers
- 468 people
- Sponsor
- Centro de Endocrinologia Experimental y Aplicada